Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) reported Revenue from Operations for Q2 FY23 of ₹63,318 Crore up from ₹57,896 Crore year on year, a growth of 9%. Global Generics Segment surged by 18% to ₹56,009 Crore. Consolidated Net Profit of ₹11,142 up 12% from ₹9,958 Crore in the same quarter of the previous year. The Earnings per Share is ₹66.98 in this quarter.
Dr. Reddy’s Laboratories Limited Q2FY23; Net Profit Increased By 12%
Related Post
- Muthoot Microfin Ltd Q4FY24; 26% rise in Profits
Founded in April 1992, Muthoot Microfin Limited, a subsidiary of Muthoot Pappachan Group, provides micro-loans…
-
United Breweries Ltd Q4FY24; 720% rise in Profits
United Breweries Limited (UBL) is engaged in the business of manufacture and sale of beer…
-
Voltas Ltd Q4FY24; 22% fall in Profits
Voltas is engaged in the business of air conditioning, refrigeration, electro - mechanical projects as…